Articles

Switzerland-based Lonza, the world’s largest CDMO by revenue, reported mixed full-year results this week but CEO Wolfgang Wienand promised significant growth potential ahead.

CEO Alberto Santagostino, who took the helm in November 2024, is looking to differentiate the Seattle-based company from other CDMOs targeting the biopharma industry.

The CDMO is building identical large-scale production facilities in the U.S. and Europe, designed to modularly and seamlessly integrate manufacturing regardless of location.

Just days apart, the company was hit with a Complete Response Letter and a clinical hold related to the FDA’s inspection findings at a third-party manufacturing facility.

Donald Trump’s presidency is creating a sense of optimism in the sector, as he looks to implement an America First trade agenda including tariffs on China, Canada and Mexico.

CEO Wolfgang Wienand touted the divestiture at last week’s J.P. Morgan Healthcare Conference in San Francisco. However, some in the audience expressed concerns.

This week, CEOs from Charles River, Thermo Fisher, and WuXi Biologics provided mixed outlooks for 2025 at the J.P. Morgan Healthcare Conference in San Francisco.

As CDMOs attend the J.P. Morgan Healthcare Conference in San Francisco, Jan. 13-16, analysts remain cautiously optimistic about the industry’s outlook in 2025.

The companies used Sutro Biopharma’s proprietary cell-free expression technology on a commercial scale to manufacture Sutro’s luvelta, an antibody-drug conjugate.

From biologics to treatments for rare diseases, these drugs will bring unique production challenges that require advanced technologies and precise processes.

Contrasting the fortunes of other hot drug classes, it is possible that cell and gene therapies may have reached their apex. So, where do they go next?

With China aggressively pursuing a strategy to become the world’s leader in biotech, America must invest in biomanufacturing to maintain its global dominance.

The week’s biggest announcement was WuXi AppTec’s sale of WuXi Advanced Therapies, its cell and gene therapy unit, to U.S.-based private equity firm Altaris.

The biopharmaceutical industry’s supply chain will again be strained. Here’s how the sector could build more resiliency.

As potentially curative therapies, CGTs offer hope to millions of patients but remain complex and difficult to manufacture at scale.

The acquisition, which took the global contract development and manufacturing organization private, is a one-off the likes of which the industry will not see again.

Though 2024 was a “mixed bag” for contract development and manufacturing organizations, a rosier picture is emerging for next year.

It may only be a matter of time until pharma companies will be able to defer to the technology for entire submissions creation

There remains huge untapped potential to increase efficiency in manufacturing and improve outcomes, and nowhere is that more pressing than for cell and gene therapies (CGTs). ...

The proposed legislation, which prevents U.S. federal funds from supporting certain Chinese contract manufacturers, was omitted from a defense bill leaving its fate in limbo.

From life-saving diabetes medications to essential respiratory treatments, several high-profile drugs will lose their patent exclusivity next year.

Drugmakers are tackling sustainability challenges to ensure energy efficiency and reduced environmental impact

This week, drug manufacturers — including Amgen, Eli Lilly, Novo Nordisk and Sanofi — announced plans to expand their production footprints in the U.S., Europe and Asia.

The future of non-clinical research may depend on integrating VCGs for a more humane and efficient approach.

A rundown of 2024’s defining pharma moments, from game-changing therapies to billion-dollar deals.

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of November 11

By embracing this standard, pharma facilities can create healthier, more sustainable buildings while contributing to a net-zero future

Here are the top things you need to know about the DSCSA, its implications, and how you can ensure your healthcare facility is compliant

How proactive maintenance safeguards quality, compliance, and reputation in pharmaceuticals.

This year’s Pharma Innovation Awards are setting new standards and quietly reshaping the future of pharma manufacturing